Jubilant Pharmova names Daniel J O'Connor as CEO of proprietary drugs biz
Published on: Dec. 2, 2025, 3:39 p.m. | Source: The Economic Times
Jubilant Pharmova has appointed Daniel J O'Connor as the CEO of its novel drugs business. O'Connor brings over 30 years of leadership experience in biotechnology and oncology. His expertise includes creating value around differentiated, IP-rich platforms. Previously, he was CEO of Ambrx Biopharma, where his leadership led to a significant increase in company valuation and its successful acquisition.
